AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q2 FY21 results · Jul–Sep 2020
AstraZeneca Pharma India reported revenue from operations of ₹209.48 crore (up 0.5% from Q2 FY20) and net profit of ₹26.34 crore (up 82.7% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a standalone basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 209.48 | 208.48 | +0.5% | 1,935.78 | −89.2% |
| Other income | 4.71 | 3.16 | +49.1% | 26.48 | −82.2% |
| Total income | 214.19 | 211.64 | +1.2% | 1,962.26 | −89.1% |
| Profit before tax | 35.57 | 31.80 | +11.9% | 263.84 | −86.5% |
| Net profit for the period | 26.34 | 14.42 | +82.7% | 186.35 | −85.9% |
| EPS, basic (₹) | 10.54 | 5.77 | +82.7% | 7.45 | not comparable |
| Net margin (%) | 12.6 | 6.9 | 9.6 |
Standalone
- Filed with BSE
- 06 Nov 2020, 15:50 IST
- Board meeting
- 05 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE